A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
← catalyst calendarNCT07254234 · readout ≤ 12 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
200estimated
Sites
1
Country
United Arab Emirates
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Dec 2025 | estimated | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cognitive Dysfunction
- Memory Disorders
Interventions
- Other: Retinal scan
- Other: Blood test
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with the Same Results on the Blood Test and Retinal Scan
measured Day 1
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed